STE STERIS plc

Copeland Capital Management LLC decreased its stake in STERIS plc by 4.4% in the third quarter, selling 8,400 shares and retaining 184,511 shares worth $45.66 million. Concurrently, several other institutional investors either purchased new positions or increased their holdings in STERIS. Company insiders also sold a significant amount of stock over the last three months, though analysts generally maintain a "Moderate Buy" rating for STERIS.

Cwm LLC significantly increased its stake in STERIS plc (NYSE:STE) by 434.3% in Q3, now holding 32,622 shares valued at approximately $8.07 million. Institutional investors collectively own 94.69% of the company, which recently beat Q3 earnings expectations and set strong FY2026 guidance. Despite this, company insiders sold over 25,000 shares worth $6.62 million in the last quarter, reducing their ownership to 1.07%.

Valley National Advisers Inc. recently acquired a new stake of 8,265 shares in STERIS plc (NYSE:STE) during the third quarter, valued at approximately $2.04 million. This investment comes amidst significant institutional ownership of 94.69% and recent insider selling totaling $6.62 million. STERIS, a medical equipment provider, reported strong Q3 results, beating EPS and revenue estimates, and has a "Moderate Buy" consensus rating from analysts with an average price target of $273.50.

Harbor Capital Advisors Inc. significantly reduced its stake in STERIS plc by 71.1% in Q3, now holding 2,559 shares valued at approximately $633,000. Despite recent insider selling totaling $6.62 million, STERIS recently surpassed quarterly EPS estimates and provided optimistic FY2026 guidance. The company, which pays a quarterly dividend of $0.63, has a market cap of $25.06 billion, a consensus analyst target of $273.50, and institutional ownership of 94.69%.

This article analyzes STERIS plc (STE) using a SWOT framework, highlighting its strengths in the infection prevention market, opportunities for growth, potential weaknesses, and external threats. It suggests that STERIS's strong market position and strategic acquisitions make its stock an attractive investment.

STERIS plc (NYSE:STE) currently has a high price-to-earnings (P/E) ratio of 36.4x, which is significantly above the market average. This elevated P/E is justified by the company's strong recent earnings growth of 17% and projected future growth of 14% per year, outpacing the broader market's 11% forecast. Investors seem to expect continued strong performance from STERIS, supporting its premium valuation.